1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis funding opportunity supports scientific research utilizing data from expanded access for investigational drugs or biological products for patients living with ALS who are not eligible for ongoing clinical trials.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial supported by a small business concern that is the FDA-designated sponsor of a drug or biological produc…. Confirm the full requirements in the official notice before applying.
The current listing shows $40,000,000 to fund an estimated four awards. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for ALS Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) are due November 10, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
ALS Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) is funded by National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
Small Business Technology Transfer (STTR) Grant is sponsored by National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). Supports cooperative R&D projects between small business concerns and research institutions, limited in time and amount, to establish the technical merit and feasibility of ideas with commercialization potential.
Enhancement of BBB Crossing of AR Degraders in GBM (Academic Research Enhancement Award (AREA) R15) is sponsored by National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). This grant supports research focusing on structurally optimizing androgen receptor (AR) degrader molecules to improve their blood-brain barrier (BBB) penetration and effectiveness in treating glioblastomas.
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleNIH's RFI on administrative burden (NOT-OD-26-118) takes comments through December 8, 2026. It asks seven questions, lists eight reforms already made, and warns that responses may be posted unredacted. Here is what NIH is really asking for, what it can and cannot change alone, and how researchers and research offices should respond.
Read article